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Abstract: Current chemotherapy treatments lack great selectivity towards tumoral cells, which leads
to nonspecific drug distribution and subsequent side effects. In this regard, the use of nanoparticles
able to encapsulate and release therapeutic agents has attracted growing attention. In this sense,
mesoporous silica nanoparticles (MSNs) have been widely employed as drug carriers owing to their
exquisite physico-chemical properties. Because MSNs present a surface full of silanol groups, they can
be easily functionalized to endow the nanoparticles with many different functionalities, including
the introduction of moieties with affinity for the cell membrane or relevant compartments within
the cell, thus increasing the efficacy of the treatments. This review manuscript will provide the
state-of-the-art on MSNs functionalized for targeting subcellular compartments, focusing on the
cytoplasm, the mitochondria, and the nucleus.
Keywords: mesoporous silica nanoparticles; targeting; subcellular targeting; endosomal escape;
mitochondria; nucleus; nanomedicine; stimuli-responsive; drug delivery
1. Introduction
Mesoporous silica materials have been widely studied since researchers from Waseda University [1]
and the Mobil Oil Corporation [2] first reported them back in the early 90s. These bulk mesoporous
materials offered (a) adjustable porous structures, (b) tunable and narrow pore size distributions
(2–30 nm), (c) high pore volumes (ca. 1 cm3/g), (d) high specific surface areas (up to 1500 m2/g) and (e)
high silanol density that allows further functionalization [3,4]. Given their excellent physico-chemical
properties, mesoporous silica materials have been widely employed in many different fields,
including catalysis [5,6], energy storage [7,8], or heavy metal adsorption [9,10], among others.
In addition to those applications, the field of drug delivery has greatly benefitted from the use of
this type of materials since Prof. Vallet-Regí and coworkers first reported their suitability to host and
release therapeutic payloads in 2001 [11]. Given their excellent properties and promising biomedical
features, scientists focused on translating such properties to the nanoscale dimension, leading to
mesoporous silica-based nanoparticles (MSNs) resembling the physico-chemical characteristics found
in the bulk materials and paving the way to multiple biomedical applications. Examples of these
applications include bone tissue regeneration [12,13], antibacterial treatment [14,15], controlled drug
delivery [16,17], gene transfection [18,19] or as templates for carbon-based biomaterials [20,21],
among others. Aside from the above-mentioned biomedical applications, MSNs have been extensively
employed as drug delivery carriers for cancer treatment. In this sense, research has focused on two
Int. J. Mol. Sci. 2020, 21, 9696; doi:10.3390/ijms21249696 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2020, 21, 9696 2 of 19
main aspects namely, achieving on-demand drug delivery and addressing the nanoparticles specifically
to cancer cells.
Because MSNs present an open porous structure, therapeutics can be easily loaded within the silica
matrix. However, for the same reason, it is very easy for them to diffuse out of the pores, leading to
nonspecific drug distribution and side effects. A smart approximation to overcome such drawback is the
use of stimuli-responsive gatekeepers, which are molecular structures able to block the pore entrances to
avoid drug leakage and open them only upon application of a specific stimulus at the tumor. The origin
of the stimuli can be external (using specific equipment) or internal (due to up-/downregulated values
of biomarkers). Examples of external stimuli are light, ultrasounds, or magnetic fields. Examples of
internal stimuli include acid pH, overexpressed enzymes, or upregulated redox species. The study of
stimuli-responsive mesoporous silica nanomaterials is beyond the scope of this review and the reader
is encouraged to check out this information elsewhere [22–24].
In this review, we will focus on how MSNs can reach tumoral tissues and cancer cells, with emphasis
on the specific targeting of subcellular organelles within target cells.
2. Basic Principles of Cancer Nanomedicine
Ideally, nanoparticles should accumulate preferentially in the tumor, where they would exert
their action without affecting healthy tissues. Nonetheless, the many different biological barriers
that nanoparticles have to face upon administration may lead to reduced efficacy of the treatments
and prevent the successful bench-to-bedside translation of nanomedicines [23,25]. Examples of such
barriers include (a) fast bloodstream clearance, (b) lack of preferential accumulation in the tumor tissues,
(c) lack of selective internalization in cancer cells, and (d) endosomal entrapment, among others.
2.1. Targeting Tumor Tissues
The rationale for using nanoparticles (of any type) in cancer treatment relies on the Enhanced
Permeability and Retention effect (EPR effect). It was first reported by Maeda and coworkers and,
indeed, it is the basis of some commercialized nanomedicines [26]. According to Maeda et al., the EPR
effect promotes the passive accumulation of nanoparticles in a tumor as a consequence of the poor
lymphatic drainage, enhanced permeability, and the hypervasculature characteristic of many solid
tumors [27].
Such passive accumulation of nanoparticles is greatly affected by features such as their size and
surface chemistry. Regarding size, nanoparticles will avoid renal clearance if they are at least 10 nm
in diameter, and will extravasate to the tumor if they are smaller than 400 nm. Nonetheless, this is
still a controversial issue regarding the size that maximizes extravasation and subsequent cancer cell
uptake. In this sense, some authors consider a size of ca. 300 nm as the most effective [28], while others
propose a size of ca. 100 nm or below [29]. The surface chemistry directly affects the behavior of
the nanoparticles in a biological fluid, as it determines the extent of plasma proteins adsorption onto
the surface. These proteins form a protein corona that provides a biological entity to the particles,
triggering their bloodstream clearance, and preventing tumor accumulation [30]. This phenomenon
can be minimized by modifying the surface of MSNs with stealth moieties, such as polyethylene
glycol or zwitterionic molecules, that prevent protein deposition through the creation of a hydration
layer [23].
Even though the EPR effect constitutes a reliable strategy for accumulating nanomedicines in
a tumor, its magnitude is greatly affected by the particularities of the tumor and the patient [31].
That non-universal passive accumulation has boosted the development of active strategies to enhance
the delivery of nanocarriers. Examples of such strategies are particle-carrying tumor-tropic cells that
spontaneously migrate to tumor tissues or nanoparticles functionalized with tumor-tropic peptides
that promote their accumulation and tumor penetration [23].
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2.2. Targeting Cancer Cells
Because cell membranes are negatively charged, the simplest approximation to trigger the cellular
uptake of MSNs is engineering a cationic surface, which will lead to the internalization through
electrostatic interactions [32]. Unfortunately, such a strategy does not provide any selectivity for
cancer cells over normal cells. A widely employed approach for promoting the accumulation of the
nanocarriers specifically in tumoral cells consists of functionalizing the surface with targeting ligands
that selectively bind membrane receptors that are overexpressed only in the tumoral cells.
There are several examples of antibody-functionalized nanoparticles. These structures show
extremely high specificity for very specific membrane receptors. In this regard, MSNs have been
modified with FDA-approved monoclonal antibodies such as Trastuzumab (HER2 receptor) [33,34]
or Cetuximab (EGFR receptor) [35,36], among others, endowing them with great ability for targeting
different types of tumoral cells. Similarly, aptamers show specificity comparable to that of antibodies,
albeit being non-immunogenic and easy to produce. For instance, they can be employed to
functionalize the surface of MSNs for targeting the EpCAM (EpCAM aptamer) [37–39] and MUC1
(MUC1 aptamer) [40,41] proteins or the nucleolin receptor (AS1411 aptamer) [42–44], among others.
Many authors have employed small commercially available molecules, such as folic acid, biotin,
or boronic acids to target overexpressed vitamin receptors [45–48] or sialic acids [49], respectively.
In addition, highly specific tumor targeting with MSNs can be achieved by synthesizing small molecules,
such as benzylguanidine analogs that show high selectivity for the upregulated norepinephrine
transporter of neuroblastoma cells [50]. In this sense, the development of peptide synthesis techniques
has allowed for the functionalization of MSNs with many different peptidic molecules with
affinity for very specific receptors. Examples of these peptides are RGD (αβ-integrins) [51,52],
NGR (CD13 receptor) [53,54], NAPamide (melanocortin-1 receptor) [55] or IL-13 (IL-13R-α2) [56],
among others. In addition to peptidic fragments, the use of biocompatible proteins has also
yielded MSNs with high tumor specificity. In this regard, the overexpression of the transferrin
receptor in many types of cancer has boosted the use of this protein as recognition moiety [57–60].
Additional approximations involve the use of proteins such as concanavalin-A (sialic acids) [61] or
Aleuria Aurantia (sialyl-Lewis X antigen) [62], among others.
3. A Step Ahead: Subcellular Cancer Cell Targeting
3.1. Targeting the Cytoplasm: Endosomal Escape
Aside from accumulating in the tumor or being preferentially internalized by tumoral cells,
nanoparticles should ideally be able to release their cargo properly within the cells. However, when
nanoparticles are internalized through endocytosis they may end up sequestered within the acidic
endosomes and lysosomes. This may have two main consequences: (1) the acidic environment might
degrade the payload and (2) membrane-impermeable and/or poorly membrane-permeable therapeutics
might not be able to exert the therapeutic action. There are two main approaches for inducing the
disruption of the endo-lysosome, those internally triggered and those externally triggered.
3.1.1. Internally Triggered Endosomal Escape
Researchers mainly take advantage of the “proton sponge effect” to induce the endosomal escape
via internal stimulus. For this disruptive effect to happen, nanoparticles should be functionalized with
chemical moieties that show buffering capacity and the pH of such vesicles, which would lead to the
basification of the endo-lysosomes. The cell would influx chloride ions along with water molecules to
counteract that proton removal. Finally, the endo-lysosomes would swell owing to the large amount of
water molecules, which would finally lead to the disruption of the vesicles and subsequent nanoparticle
release [63].
Weiss et al. developed MSNs functionalized with poly(amidoamine) dendrimers and further
modified with folic acid, triggering their selective uptake in KB cells [64]. Then, the large number of
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amino groups in the dendrimer induced the endosomal escape into the cytoplasm via proton sponge
effect, where the overexpressed glutathione triggered the release of a redox-responsive derivative of
colchicine from the mesopores. Chen et al. recently reported metal-phenolic networks consisting of
tannic acid complexed with FeIII ions as coatings for MSNs [65]. At pH > 7, FeIII ions were complexed
to three tannic acid molecules, forming a tris complex. However, the acid pH of the endo-lysosomes
induced a tris-to-bis complex transition as a consequence of the protonation of the phenolic molecules
of tannic acid, which finally led to the endosomal escape of the particles in MDA-MB-231 cancer cells.
Polyethyleneimine (PEI) is a cationic polymer that finds broad application for the transfection of
nucleic acids, which need to be released in the cytoplasm to exert their therapeutic action. A major
drawback of chemotherapy is drug resistance, which renders the cytotoxic less effective. In this sense,
a smart approach consists of transfecting a gene capable of inhibiting the drug-resistant character of
cancer cells and subsequently delivering a cytotoxic to the sensitized cells. In this regard, Chen et al.
functionalized the surface of MSNs with PEI to incorporate a short hairpin RNA (shRNA) for silencing
ABCG2 protein [66]. PEI successfully triggered the escape and induced the release of doxorubicin and
the shRNA. As a consequence, the drug-resistant protein ABCG2 was no longer produced, diminishing
the amount of doxorubicin excreted by the cancer stem cells and inhibiting their proliferation both
in vitro and in vivo. TWIST is a protein that is linked to drug resistance and cancer progression.
Sánchez-Salcedo et al. reported a PEI-coated Fe3O4@SiO2 core-shell nanocarrier with reduced protein
adsorption features for the knockdown of TWIST [67]. Upon accomplishment of the PEI-mediated
endosomal escape through proton sponge effect, an anti-TWIST small interfering RNA (siRNA) and
the chemotherapeutic daunorubicin were released. Then, the siRNA increased the sensitivity to the
drug, resulting in enhanced cytotoxicity to ovarian cancer cells OVCAR8 (Figure 1).
Figure 1. (A) Schematic representation of the mesoporous silica nanoparticles (MSNs). MSNs were
functionalized with PEI for siRNA loading and further modified with a phosphorylcholine derivative
to introduce zwitterionic groups to endow the MSNs with antifouling features. (B) Cytotoxic effect of
the functionalized MSNs. The highest cytotoxicity was observed for the groups containing the siRNA
and the drug daunorubicin. Reproduced from Ref. [67] with permission from Elsevier.
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The endosomal escape can also be accomplished by using amino acids with buffering capacity.
In this sense, the imidazole ring of histidine has a pKa of ca. 6 [68] and shows buffering capacity at
the pH of the endocytic pathway. Bilalis et al. reported the functionalization of the surface of MSNs
with poly(L-histidine) using a surface-initiated ring-opening polymerization [69]. They showed that
the peptidic coating could act as pH-responsive gatekeeper but they did not verify the endosomal
escape features of the system. Nonetheless, a dramatic increase in the zeta potential was observed
at pH 5 (that of the lysosomes), compared to that at pH 7.4, demonstrating the buffering capacity
of the system and its usefulness as endosomal escape agent. Similarly, Li et al. took advantage
of just the imidazole motif to design dendritic MSNs for co-delivery of doxorubicin and survivin
shRNA-expressing plasmid [70]. The surface of the particles was functionalized with imidazole to
accomplish endosomal escape and the shRNA was electrostatically loaded on the surface. The release
of the shRNA in the cytoplasm led to the inhibition of survivin, increasing the sensitization of QGY-7703
cells to the co-delivered doxorubicin in vitro and in vivo.
3.1.2. Externally Triggered Endosomal Escape
Aside from taking advantage of the acid pH of the endo-lysosomes, it is possible to induce the
escape of the particles by functionalizing the surface of the MSNs with chemical moieties able to
generate reactive oxygen species (ROS) upon light irradiation. The generation of ROS induces the
peroxidation of the lipid bilayer of the endo-lysosomes, altering its fluidity and permeability and
triggering its destabilization and subsequent nanoparticle escape [71].
The simplest approximation consists of loading a photosensitizer within the mesoporous silica
matrix. Hai et al. designed DNA-capped MSNs loaded with indocyanine green for chemo-photothermal
therapy [72]. Indocyanine green is a photothermal and photosensitizing agent that generates
heat and ROS upon irradiation with near-infrared light (780 nm). Hence, the nanoparticles first
internalized in HeLa cells and were then irradiated with the laser, leading to the generation of ROS that
triggered the destabilization of the endosomes. In addition, the heat generated by the photosensitizer
induced the dehybridation of the DNA strands, triggering the doxorubicin release in the cytoplasm.
The photosensitizer can also be grafted on the surface. Niedermayer et al. reported pH-responsive,
folic acid-targeted MSNs to which the photosensitizer AlPcS2a was grafted [73]. The nanocarrier was
efficiently internalized in KB cells thanks to the overexpressed folate receptors and then the acid pH
triggered the release within the endo-lysosomes. After that, the particles were irradiated with red
light (639 nm), generating ROS and inducing the endosomal escape that allowed for the release of a
membrane-impermeable compound in the cytoplasm.
The generation of ROS can also be employed for cleaving ROS-responsive bonds, such as those
based on aminoacrylates. Vijayakameswara Rao et al. engineered a gatekeeper for MSNs based on a
Gd-DOTA complex grafted to the surface through an aminoacrylate-based bond [74]. The surface was
further functionalized with a polyethylene glycol containing the photosensitizer chlorin e6 and the
particles were incubated with SCC-7 cells. Then, upon application of 660-nm light, the photosensitizer
induced the generation of 1O2 that triggered the cleavage of the stimuli-responsive bond as well as
the endosomal escape, leading to enhanced drug release and cytotoxic effect both in vitro and in vivo.
Martínez-Carmona et al. reported the use of photosensitizers as both ROS generators and gatekeepers
for MSNs [75]. A porphyrin able to generate 1O2 when irradiated with visible light was grafted to
the particles via an aminoacrylate-based bond, sealing the pore entrances in the dark. The particles
were readily internalized in human osteosarcoma cells where they localized in the lysosomes. Then,
the application of visible light induced the generation of ROS that triggered the destabilization of the
vesicle and the cleavage of the stimuli-responsive linker, thereby leading to the release of the cargo in
the cytoplasm of the cells (Figure 2).
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Figure 2. (A) Schematic representation of MSNs engineered for achieving endosomal escape
through reactive oxygen species (ROS) generation. A visible light-sensitive porphyrin is grafted
to the surface through a ROS-responsive linker that is cleaved when upon light irradiation,
triggering endosomal escape and drug release. (B) Calcein assay for assessing endosomal escape:
Calcein is a membrane-impermeable dye that is unable to cross the lipid bilayer of the endo-lysosomes
in the dark. When light is applied, ROS generated destabilizes the membrane and calcein diffuses into
the cytoplasm. Reproduced from Ref. [75] with permission from The Royal Society of Chemistry.
3.2. Mitochondrial Targeting
One of the main drawbacks of current antitumoral drugs, such as doxorubicin or topotecan,
is the development of drug resistance, which renders the drugs useless and leads to the failure of the
treatments. Given that each chemotherapeutic exerts its action on a particular organelle, delivering the
drugs near such a particular organelle may help to avoid drug resistance. In this sense, researchers
have paid much attention to mitochondrial targeting, as mitochondria are involved in cell apoptosis,
cell metabolism, and ROS generation [63,76].
3.2.1. Triphenylphosphine Derivatives to Target Mitochondria
Because the mitochondrial membrane is negatively charged, the use of positively charged
substances seems appealing for accumulating the cytotoxics within the mitochondrial matrix.
In this sense, current approximations for improving mitochondrial internalization include
linking a lipophilic cation (alkyltriphenylphosphonium and others) to a bioactive compound.
Among them, Triphenylphosphine derivatives (TPP) are one of the most promising and widely
used mitochondria-targeting ligands, especially in combination with MSNs [63,76].
Qu Q et al. reported TPP-functionalized MSNs (MSNP-PPh3) loaded with doxorubicin [77].
Co-localization of mitochondria and MSNs was demonstrated in HeLa tumoral cells by fluorescence
analysis, showing the targeting efficacy. The authors also demonstrated the effective release of
doxorubicin to mitochondria by MSNP-PPh3 and a successful escape from lysosomes. The DOX-loaded
nanomaterial led to reduced cellular adenosine triphosphate (ATP) production and mitochondria
membrane potential, indicating mitochondria dysfunction and resulting in a significant reduction in
HeLa cell viability. Cai X et al. reported a new class of mitochondria-targeted three-dimensional (3D)
dendritic MSN nanospheres for the delivery of high concentrations of the hydrophobic photosensitizer
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chlorin e6 (Ce6) in A549 lung cancer cells (Figure 3) [78]. Photodynamic therapy (PDT) in cancer
presents some limitations, such as short lifetime or tumor hypoxia. To address the latter, the authors
synthesized peroxidase-like nanozyme Pt NPs with ability to catalyze the conversion of intracellular
H2O2 into oxygen in the tumoral cells. Then, MSNs were modified with the Pt NPs and further
functionalized with TPP for mitochondrial targeting (Pt-DMSNs-TPP/Ce6). This nanocarrier induced
an intracellular ROS burst in A549 cells due to the mitochondrial targeting capacity, resulting in
cell apoptosis. Viability studies exhibited 80% of tumoral cell death induced by Pt-DMSN-TPP/Ce6
nanosystem upon light irradiation at 660 nm, eradicating the hypoxia problem. An alternative strategy
was developed by Cheng R et al. [79] to clarify the mechanism of selenite (Na2SeO3)-mediated cancer
cell death. For that purpose, the authors designed a mitochondria-targeted nanoprobe (Mito-N-D-MSN)
able to monitor the changes in mitochondrial hydrogen selenide (H2Se) and superoxide anion (O2·-)
changes simultaneously in HepG2 tumoral cells. This MSN-based nanodevice was loaded with
two fluorescent nanoprobes and further modified with TPP. The in vitro results indicated that the
mitochondrial H2Se content gradually increased, while the O2·- content remained unaffected in HepG2
cells under hypoxic environments, suggesting that the antitumoral mechanism of Na2SeO3 comprises
non-oxidative stress in the real tumor microenvironment.
Figure 3. Schematic representation of mitochondria-targeted dendritic MSNs for photodynamic therapy.
MSNs were functionalized with triphenylphosphonium (TPP) for mitochondrial targeting and loaded
with the photosensitizer Ce6. Then, Pt nanoparticles showing peroxidase-like nanozyme activity were
attached to the surface to catalyze the conversion of intracellular H2O2 into oxygen in the tumoral cells.
Finally, Ce6 generated ROS upon light irradiation, leading to synergistic cell death. Reproduced from
Ref. [78] with permission from The Royal Society of Chemistry.
Aside from endowing the MSNs with mitochondrial targeting, they can be modified to achieve
sequential cell-to-organelle recognition. In this regard, Sun K et al. developed an iron oxide@SiO2
core-shell nanosystem functionalized with folate and TPP for membrane and subsequent mitochondrial
targeting (Fe3O4@MSN-TPP/PEG-FA) for cancer therapy [80]. The nanocarrier was loaded with
doxorubicin and the catalase inhibitor 3-amino-1,2,4-triazole (AT). Doxorubicin triggered nicotinamide
adenine dinucleotide phosphate oxidases (NOXs) activation, which induced the formation of H2O2.
Catalase inhibition led to the preservation of H2O2, forming hydroxyl radicals in the presence of the
iron ions nearby mitochondria and exerting significant death on MGC-803 and MCF-7 cells.
A similar approximation was reported by Wang L et al., who developed TPP-functionalized
MSNs coated with a folic-acid targeted, pH-controlled lipid bilayer [81]. The particles were loaded
with 2,2’-azobis[2-(2-imidazolin-2-yl) propane] dihydrochloride (AIPH) and the liposomes were
loaded with docetaxel, forming the final core-shell system by self-assembly throughout the liposomes
hydration (AIPH/MSN-TPP@Lipo/DTX-FA). AIPH/MSN-TPP@Lipo/DTX-FA nanosystem successfully
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internalized in breast tumoral cells through FA receptor-mediated endocytosis. The liposomes were
destabilized by the acid pH of the lysosomes and docetaxel was released. Then, the AIPH/MSN-TPP
nanoparticles escaped the lysosomes and targeted mitochondria, releasing AIPH and inducing
temperature-activated alkyl radicals burst (oxidative damage), showing synergistic effect both in vitro
and in vivo. The selective recognition of tumoral cells can also be accomplished using hyaluronic
acid to target overexpressed CD44 receptors. In this sense, Naz S et al. reported enzyme-responsive
MSNs bearing TPP on the surface and further functionalized with hyaluronic acid (HA) as membrane
targeting and pore capping agent [82]. HA triggered the internalization in CD44 receptor-positive cells
and predominantly accumulated in mitochondria thanks to TPP. Then, HAase, which is overexpressed
in cancer cells, induced the degradation of HA and triggered DOX release in MGC-803 tumoral cells,
leading to significant cell death.
3.2.2. Other molecular Agents to Target Mitochondria
Even though most of the systems are based on using TPP for targeting the mitochondria, there are
some other approximations. For instance, Ahn J et al. proposed the use of guanidinium derivatives (GA)
as mitochondrial targeting agents (Figure 4) [83]. They designed GA-targeted, DOX-loaded Fe3O4@SiO2
nanoparticles (DOX/GA-Fe3O4@MSNs) The nanosystem showed competent mitochondria-targeting
capability in a co-localization, microscopic, and fluorometric analysis. DOX/GA-Fe3O4@MSNs induced
a significant decrease in HeLa tumoral cell viability while the GA-Fe3O4@MSNs did not induce
any change. Remarkably, GA induced higher mitochondrial targeting than that observed for a
control group of such nanoparticles functionalized with TPP, highlighting the high affinity of GA.
Another approach was reported by Liu J et al., who developed mitochondria-targeted, silica-coated
gold nanorods (AuNR@MSN) by functionalizing the surface with the mitochondria-targeting peptide
RLA ([RLARLAR]2) [84]. The hybrid was loaded with indocyanine green for dual photodynamic and
photothermal therapy and the pores were capped with β-cyclodextrin and further functionalized with
RLA. In addition, a charge-reversible polymer was hosted to provide stealth property. In this context,
the weak acidity in the tumor tissue could produce the dissociation of the charge-reversible polymer,
exposing the RLA peptide for cell internalization and subsequent mitochondria accumulation in MCF-7
tumor cells. After 808 nm NIR light irradiation, AuNR@MSN-ICG-RLA/CS (DMA)-PEG induced
tumor cell apoptosis in vitro because of ROS generation and local hyperthermia via mitochondria.
These results were confirmed in vivo where this nanodevice showed antitumoral effect with minimal
side effect, after specific accumulation at tumor location, improving combination therapy of PDT
and PTT.
Figure 4. Schematic representation of MSNs functionalized with guanidinium derivatives for
mitochondrial targeting. The GA-functionalized MSNs accumulated faster into the mitochondria,
compared with the TPP derivatives. Reproduced from Ref. [83] with permission from The Royal Society
of Chemistry.
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3.2.3. Compounds Acting on Mitochondria
Hu J et al. [85] proposed a new approach for enhanced tumor chemotherapy based on ROS-triggered
self-accelerating drug release MSNs (T/D@RSMSNs). The particles were loaded with DOX and
α-tocopheryl succinate (α-TOS) and gated by PEGylated β-cyclodextrins through a ROS-cleavable
thioketal linker. α-TOS is a vitamin E analog that acts as a ROS mediator after interacting with the
mitochondrial respiratory complex II. T/D@RSMSNs released doxorubicin and α-TOS and induced
an increase in intracellular ROS concentration in human breast cancer (MCF-7) cells, triggering the
cleavage of the thioketal linker TK linkage for further doxorubicin release, both in tumoral MCF-7
cells in vitro studies and in BALB/c nude mice tumor xenograft models, decreasing tumor weight and
volume, compared with others similar nanosystems based on ROS-responsive strategies.
Aside from conventional chemotherapeutics, researchers have paid attention to the encapsulation
of less typical drugs with antitumoral activity. In this regard, Choi et al. developed PEGylated
polyaminoacid-capped MSNs (CMSN-PEG) for celastrol delivery to cancer cells [86]. Celastrol is
extracted from the traditional Chinese medicinal plant Tripterygium wilfordii and several studies
have shown antitumoral effects in vitro and in vivo by targeting mitochondria. The celastrol-loaded
nanosystem showed controlled drug release and induced apoptosis of SCC-7, SH-SY5Y, and BT-474
tumoral cell lines in vitro, related to decreased HIF-1α protein levels and other proteins implicated in
mitochondrial apoptosis pathway. In vivo, this novel nanosystem significantly decreased solid tumor
presence in SCC7 tumor-bearing xenograft model, inducing a rise in apoptotic markers and stimulating
the reduction of CD31 and Ki67 proliferation markers. An alternative tumor tissue-specific drug is
Umbelliferone, a natural coumarin derivative. Kundu M et al. [87] designed umbelliferone-loaded
MSNs capped with pH-sensitive poly acrylic acid (PAA) and further functionalized with folic acid
(Umbe@MSN-PAA-FA). Umbe@MSN-PAA-FA nanosystem induced a decrease in cell viability due to
both oxidative stress and mitochondrial damage in MCF-7 cells, compared with free Umbelliferone.
This nanohybrid displayed discretely drug loading capability, enhanced tumoral cell targeting,
and effective pH-controlled Umbelliferone release properties. Thanks to the optimal drug bioavailability
in the tumoral mass, Umbe@MSN-PAA-FA nanocarrier showed a significant decrease in tumor size on
an in vivo solid tumor model in Swiss albino mice, compared with free umbelliferone, without negative
effects in other vital organs.
Luo GF et al. [88] attached a TPP-modified antibiotic peptide (KLAKLAK)2 to the surface of
topotecan-loaded MSNs via disulfide bonds. Then, a charge reversal polyanion poly(ethylene glycol)-
blocked-2,3-dimethylmaleic anhydride-modified poly(L-lysine) (PEG-PLL(DMA)) was added to the
surface via electrostatic interactions. In this manner, the DMA block degraded in the acidic tumor
microenvironment, removing the outer shielding layer and triggering the uptake in increasing
ubiquitous KERATIN- forming tumor cell line HeLa. Finally, the TPP-modified peptide was released
from nanodevice by the overexpressed glutathione, targeting the mitochondria and showing synergistic
specific cancer cell death.
An alternative new antibacterial peptide delivery strategy was designed by Cao J et al. as a
cancer treatment approach [89]. Given that many antibacterial peptides lead to in hemolysis in vivo,
Cao J et al. synthesized a novel antibacterial peptide RGD-hylin a1 with reduced hemolysis and loaded
it within the pores of the MSNs (RGD-hylin a1-MSN). This nanocarrier released RGD-hylin a1 in a
pH-controlled manner at acid pH, inducing the reduction of mitochondrial membrane potential and
leading to cancer cell death, and non-effect in pH = 7. In vivo, this nanocarrier reduced (50–60%) solid
tumor volume and weight after intravenous administration in tumor-bearing mice at low dosage via
intravenous injection compared with control non-treated group, without inducing toxicity.
As shown in the review, MSNs have been widely engineered for targeting the mitochondria with
extraordinary efficacy, increasing cancer cell death and decreasing tumor growth and size in vitro
and in vivo. Nonetheless, it should be mentioned that these nanosystems also find application in
other diseases, such as Alzheimer’s disease (AD). In this sense, several AD therapies have focused on
amyloid-β targeted treatments, but recent studies have demonstrated that tau pathway is connected
Int. J. Mol. Sci. 2020, 21, 9696 10 of 19
with clinical expansion of AD signs, indicating that can be a possible therapeutic target. In this regard,
Chen Q et al. loaded the MSNs with the tau aggregation inhibitor methylene blue (MB) and further
functionalized them with a hyperphosphorylated tau binding agent (Amino-T807) [90] as well as
ultrasmall ceria nanocrystals (CeNCs) and iron oxide nanocrystals (IONCs). CeNCs exhibited high
ROS activity and antioxidant properties in mitochondrial oxidative-stress-induced damage therapy in
Alzheimer’s disease, acting as tau hyperphosphorylation inhibitors. Both in vitro and in vivo results
showed that this complex nanocarrier decreased Alzheimer’s disease consequences, diminishing
mitochondrial oxidative stress and inhibiting tau hyperphosphorylation and neuronal apoptosis,
yielding a synergistically improved therapeutic alternative.
3.3. Nuclear Targeting
As previously mentioned, the problems that chemotherapeutics have to face are drug resistance
and subsequent cell exocytosis. In this sense, drug-loaded nanocarriers can also be functionalized for
targeting the nucleus, delivering their cargo nearby their target [76,91]. It is well-known that there are
numerous pore complexes of 20-70 nm in diameter on the nuclear membrane, which are the specific
passages through which substances of up to 40-60 kDa diffuse from and to the cytoplasm. Given that the
passive diffusion through the nuclear envelope is restricted by the size of those complexes, nanoparticles
need a nuclear localization signal or sequence (NLS), which are peptides for recognizing specific
transport receptors to initiate the trans-nuclear membrane penetration process [92]. The internalization
into the nucleus is mediated by importins. First, NLS peptides bind importin α and, then, importin β
binds them to form a complex that finally transports the target compound into the nucleus [93].
Wu M et al. reported the synthesis of PEI-coated, TAT-targeted MSNs for nuclear transfection of a
model plasmid that encoded green fluorescent protein [94]. They demonstrated that the combination
of PEI + TAT provided the highest plasmid loading capacity, probably due to the highly positive
surface, and protected the nucleic acids from degradation. Finally, they demonstrated the nuclear
targeting and efficiently encoded the green protein without affecting the viability of the cells (Figure 5).
The most extended strategy involves the design of dual-targeted nanoparticles bearing a membrane
and a nuclear targeting for sequential cell-to-organelle recognition. In this regard, Zhao J et al. reported
MSNs whose surface was functionalized with a fluorescent derivative of the HIV-1 transactivator
(NLS) peptide (TAT-FITC), for nuclear targeting, and the peptide YSA-BHQ1 for binding the EphA2
membrane receptor [93]. In addition, citraconic anhydride was used to invert the charge of the TAT
peptide in neutral or weak alkaline conditions so that the positively charged YSA peptide could
combine with TAT through electrostatic attraction, avoiding nonspecific TAT interactions with normal
cells. The nanocarrier was successfully internalized by MCF-7 tumoral cells via YSA recognition. Then,
the acid pH of the lysosomes cleaved the citraconic anhydride and triggered the lysosomal escape
and subsequent nuclear translocation, where DOX was rapidly released, inducing an apoptotic effect
in the cells. Wu Z et al. synthesized dual-targeted, enzyme-responsive MSNs for anticancer therapy
and imaging [95]. They doped the MSNs during the synthesis with Eu3+ and Gd3+ for carrying out
bioimaging. Then, TAT was attached to the surface and the particles were further coated with HA to
mask the peptide as well as to provide membrane targeting and gatekeeping. The in vitro evaluation
showed that HA degraded upon a lysosome HA decomposition by HAase, inducing the exposition of
nuclear target TAT, releasing camptothecin into the nucleus and stimulating tumoral cell death.
Murugan C et al. developed topotecan-loaded MSNs functionalized with the TAT peptide, to which
RGD-functionalized poly(acrylic acid) and citraconic anhydride-metformin were added [96]. The latter
components acted as gatekeepers and as masking agents of the positively charged TAT. The nanosystem
was effectively internalized by MDA-MB-231 tumoral cells via integrin targeting. The lysosomal pH
triggered metformin drug release and exposed again the TAT peptide, achieving endosomal escape and
nuclear translocation. Then, topotecan was successfully released into the nucleus, leading to synergistic
antitumoral effect and reducing tumor growth without significant toxicity associated with mice.
Int. J. Mol. Sci. 2020, 21, 9696 11 of 19
Figure 5. (a) Schematic representation of TAT-targeted MSNs for nucleic acid transfection. The plasmid
was loaded into the PEI-TAT mesh, leading to enhanced nuclear accumulation and encoding green
florescence protein through a model plasmid. (b) Schematic representation of the mode of action of the
nanocarrier. Reproduced from Ref. [94] with permission from Wiley.
Aside from using NLS peptides, the nucleus can be targeted by taking advantage of the properties
of gold nanoclusters, which show unique nuclei staining properties. In this sense, Croissant et al. [97]
reported the synthesis of gemcitabine/doxorubicin-loaded MSNs functionalized with BSA-coated gold
nanoclusters (MSN-AuNC@BSA) acting as gatekeepers via electrostatic interactions. Drug release
took place at acid pH owing to the disruption of such interactions, triggering HeLa tumoral cell death.
In addition, the BSA-coated nanoclusters were released at acid pH as well, being able to stain the
nuclei for cancer cell imaging. The authors showed a robust specific fluorescence of the nanocarrier in
the tumors induced in mice, indicating the high value of this type nanotheranostic platform based on
MSNs and gold-protein clusters in cancer therapy and diagnosis.
The different nanosystems able to target mitochondria or nucleus are summarized in Table 1:
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Table 1. Different approximations for the design of organelle-targeted MSNs.
Carrier Type Organelle Organelle TargetingMolecule Drug Cell Line(s) In Vivo Application Ref
MSNs
Mitochondria
TPP DOX HeLa X Cancer [77]
DMSNs TPP X A549 X Cancer [78]
MSNs TPP X HepG2 X Cancer [79]
Fe3O4@MSN TPP DOX MGC-803, MCF-7 X Cancer [80]
MSNs TPP AIPH and DTX MDA-MB-231 Mice Cancer [81]
MSNs TPP DOX MGC-803 X Cancer [82]
Fe3O4@MSN Guanidinium DOX HeLa X Cancer [83]
AuNR@MSN (RLARLAR)2 X MCF-7 Mice Cancer [84]
MSNs α-tocopheryl succinate DOX MCF-7 Mice Cancer [85]
MSNs Celastrol Celastrol SCC-7,SH-SY5Y, BT-474 Mice Cancer [86]
MSNs PAA Umbelliferone MCF-7 Mice Cancer [87]
MSNs TPP, (KLAKLAK)2 Topotecan HeLa X Cancer [88]
MSNs RGD-hylin a1 RGD-hylin a1 HeLa Mice Cancer [89]
MSNs Amino-T807 Methylene blue SH-SY5Y Mice Alzheimer’sdisease [90]
MSNs
Nucleus
TAT DOX MCF-7 X Cancer [93]
MSNs TAT Plasmid Hela Mice Cancer [94]
MSNs TAT Camptothecin HeLa X Cancer [95]
MSNs TAT Topotecan MDA-MB-231 Mice Cancer [96]
MSNs TAT Gemcitabine,doxorubicin HeLa Mice Cancer [97]
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4. Future Perspectives and Conclusions
The great physico-chemical and biocompatible features that MSNs exhibit has fueled the design of
many different nanosystems specially designed for the treatment of various diseases. Yet it is true that
no silica-based nanocarrier has reached the clinic so far, the US Food and Drug Administration (FDA)
recognizes silica as safe. It is usually employed as excipient in drug formulations and as a dietary
supplement [98,99]. Indeed, there are already examples of studies on silica materials conducted or
being conducted in humans, highlighting the promising future that this kind of materials may have
and the interest that they arouse in clinicians.
Phillips et al. reported a human trial where they evaluated the usefulness of small 7-nm
silica nanoparticles (c-dots) for imaging purposes in patients suffering metastatic melanoma [100].
The c-dots were functionalized with the cyclic peptide cRGDY for targeting endothelial cells involved in
angiogenesis, observing that the silica nanoparticles could target the tumor while being well tolerated
by the patients. In view of such promising results, the Memorial Sloan Kettering Cancer Center
is currently recruiting candidates to evaluate whether c-dots can be employed for detecting lymph
nodes during cancer surgery (ClinicalTrials.gov Identifier: NCT02106598) and imaging brain tumors
(ClinicalTrials.gov Identifier: NCT03465618).
Regarding mesoporous silica materials, Bukara et al. reported the first study of ordered mesoporous
materials in men [101]. They formulated poorly soluble fenofibrate in 500-nm mesoporous silica,
which was orally administered to healthy men (average age: 46.4), demonstrating that the mesoporous
silica materials were well-tolerated and safe. In addition, they showed that higher drug absorption
was achieved compared to a marketed product. Furthermore, the Karolinska Institutet (Sweden) has
recently submitted to the FDA the results (pending evaluation) of a human trial evaluating the safety
profile of doses of up to 9 g/day of mesoporous silica microparticles as a food additive (ClinicalTrials.gov
Identifier: NCT03667430).
It has been made clear throughout this review that incorporating subcellular targeting moieties
may increase the efficacy of nanoparticle-based cancer treatments because drugs can be delivered
closer to their target (mitochondria, nucleus . . . ). Hence, given that there is real interest in translating
this kind of nanomaterials into the clinic, the next step should be the design of clinical trials involving
(1) mesoporous silica nanoparticles, so their promising features would be finally verified and (2) simple
but effective structures for increasing the accumulation of the particles in the tumors along with the
subcellular targeting or relevant organelles.
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